Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
04/13/2017 04/18/2017 04/19/2017 04/20/2017 04/21/2017 Date
105.45(c) 104.45(c) 103.95(c) 103.55(c) 103(c) Last
286 436 351 194 262 083 230 467 417 507 Volume
0.00% -0.95% -0.48% -0.38% -0.53% Change
More quotes
Financials (€)
Sales 2017 15 585 M
EBIT 2017 3 305 M
Net income 2017 1 846 M
Debt 2017 9 715 M
Yield 2017 1,23%
Sales 2018 16 036 M
EBIT 2018 3 571 M
Net income 2018 2 081 M
Debt 2018 7 606 M
Yield 2018 1,32%
P/E ratio 2017 24,06
P/E ratio 2018 20,41
EV / Sales2017 1,48x
EV / Sales2018 1,30x
Capitalization 13 312 M
More Financials
Company
Merck KGaA engages in the manufacturing of pharmaceutical and chemical products.It operates through the following segments: Healthcare, Life Science, and Performance Materials.The Healthcare segment comprises of the businesses that were reported separately as the Merck Serono and Consumer Health... 
Sector
Pharmaceuticals
Calendar
04/28Shareholder meeting
More about the company
Surperformance© ratings of Merck KGaA
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK KGAA
04/20 MERCK : Researchers from Merck KGaA Describe Findings in Granulocytes (Compariso..
04/20 Merck to expand online business 'dramatically'
04/18 MERCK : Darmstadt, Germany Furthers Commitment Towards Elimination of Schistosom..
04/14 Slab Gel Electrophoresis Market 2017 - 3M Purification, Merck KGaA, AB Sciex,..
04/12 MERCK : EU Horizon 2020 Project “HyperOLED” Successfully Launched
04/06 MERCK KGAA : Darmstadt, Germany Advances R&D Strategy through Unique Development..
04/06 MERCK : MilliporeSigma Announces First Stops in National Curiosity Cube Tour
04/05 MERCK : MilliporeSigma Announces First Stops in National Curiosity Cube™ T..
04/04 Merck KGaA spinoff licenses IBD drug to Eisai joint venture
04/03 MERCK : MilliporeSigma Introduces Next-Generation High-Sensitivity Protein Detec..
More news
Sector news : Specialty & Advanced Pharmaceuticals
04/22DJNovartis Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/19DJSHIRE : Files 8K - Other Events
04/19DJFARON PHARMACEUTICALS OY : Appoints Two Non-Executive Directors
More sector news : Specialty & Advanced Pharmaceuticals
4-Traders Strategies on MERCK KGAA 
2016Towards the breakout of a major resistance level
2014Prices move higher as positive news are released
More Strategies
Latest Tweets
04/22FY2021 Earnings Estimate for Merck & Co., Inc. $MRK Issued By Jefferies G.. 
04/22ICYMI: J&J faces its second rival Remicade knockoff as FDA gives Merck a ..
5
04/22Merck & Co.'s underperform rating reiterated at Jefferies Group LLC. $51... 
04/22Merck : Announces New Phase 2 Data on Investigational Triple Combination Ther.. 
04/21FDA approval of copycat Remicade puts Merck $MRK in odd position of selling b..
7
More tweets
Qtime:116
News from SeekingAlpha
04/15 The Market Is Going To Fall - My Dividend Growth Shopping List
03/31 AMERICAN ASSOCIATION FOR CANCER RESE : Combinations, Oncolytic Viruses, And More
03/23 FDA OKs Merck KGaA and Pfizer's avelumab for rare type of skin cancer
03/23 BeiGene, Another Beijing Venture In Cancer Therapy
03/10 Pfizer And Merck Go For An Even Longer Throw Of The Javelin
Advertisement
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 110 €
Spread / Average Target 7,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA3.88%14 277
ABBVIE INC1.85%101 702
KYOWA HAKKO KIRIN CO L..16.81%9 962
JAZZ PHARMACEUTICALS P..40.18%9 131
CONVATEC GROUP PLC26.34%7 386
ZHANGZHOU PIENTZEHUANG..23.87%4 971
More Results